EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1)



Prevention of islet allograft rejection in diabetic mice by targeting Janus Kinase 3 with 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline (JANEX-1)



Arzneimittel-Forschung 53(9): 648-654



Janus kinase (JAK) 3-deficient mice were not able to reject allogeneic islet allografts. The JAK3 inhibitor 4-(4'-hydroxyphenyl)-anino-6,7-dimethoxyquinazoline (CAS 202475-60-3, JANEX-1, WHI-P131) prevented the rejection of islet allografts in mice with a normal JAK3 expression status.

(PDF emailed within 0-6 h: $19.90)

Accession: 012448406

Download citation: RISBibTeXText

PMID: 14558439

DOI: 10.1055/s-0031-1299807



Related references

Prevention of islet allograft rejection in diabetic mice by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Arzneimittel-Forschung 53(9): 648-654, 2003

Islet allograft rejection is prevented by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Diabetes Research & Clinical Practice 50(Suppl 1): S183, September, 2000

Prevention of development of type 1 diabetes in NOD mice by targeting Janus kinase 3 with 4- -amino-6,7-dimethoxyquinazoline. Diabetes Research & Clinical Practice 50(Suppl 1): S183, September, 2000

Targeting Janus kinase 3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice. Diabetes 52(Supplement 1): A274-A275, 2003

Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97). Journal of Pharmacology and Experimental Therapeutics 295(3): 912-926, 2000

In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline. Clinical Cancer Research 5(10): 2954-2962, 1999

CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: Structural basis for inactivation by regioselective O-demethylation. Drug Metabolism and Disposition 30(1): 74-85, 2002

CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation. Drug Metabolism and Disposition: the Biological Fate of Chemicals 30(1): 74-85, 2001

Prevention of fatal thromboembolism in mice by selectively targeting Jak 3 kinase in platelets with 4- -amino-6,7-dimethoxyquinazoline. Blood 96(11 Part 1): 273a, November 16, 2000

Treatment of allergic asthma by targeting Janus kinase 3-dependent leukotriene synthesis in mast cells with 4- amino-6,7-dimethoxyquinazoline. Journal of Pharmacology & Experimental Therapeutics 295(3): 912-926, December, 2000

Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1. American Journal of Reproductive Immunology 58(2): 75-97, 2007

Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302(5646): 875-878, 2003

Prevention of acute lung allograft rejection in rat by the janus kinase 3 inhibitor, tyrphostin AG490. Journal of Heart and Lung Transplantation 24(10): 1557-1564, 2005

Pharmacokinetics and in vivo toxicity of Janus kinase 3 inhibitor WHI-P131 -amino-6,7-Dimethoxyquinazoline. Blood 94(10 SUPPL 1 PART 2): 197b, Nov 15, 1999